Marvel Biosciences Corp.

About Marvel Biosciences Corp.

Marvel Biosciences is a Canadian biotechnology company focused on developing breakthrough therapies for complex neurological and neurodevelopmental disorders such as autism spectrum disorder, Rett syndrome, and Fragile X syndrome. They aim to reinvent existing molecules through precise chemical innovation to create safer, faster, and more effective treatments, accelerating development while reducing risk.

Products & Services

MB-204:Lead therapeutic candidate targeting neurological and neurodevelopmental disorders, with demonstrated preclinical efficacy and advancing toward first-in-human studies.

Non-Hallucinogenic Neuroplasticity Program:A program focused on developing therapies for neurodevelopmental disorders without hallucinogenic effects.

Specialties

Neurological disorders Neurodevelopmental disorders Autism spectrum disorder Rett syndrome Fragile X syndrome Chemical innovation in drug development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 600000 MR: - FA: $600,000 FAN: 600000	D: 2026-03-30 FD: 2026-03-30	1 investors

Grant Latest

2026-03-30

$600K

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

J. Roderick Matheson

Chief Executive Officer and Director

D

Dr. Mark Williams

President, Chief Science Officer and Director

H

Harry Nijjar

Chief Financial Officer

J

Jacqueline Groot

Corporate Secretary

N

Neil A. Johnson

Director

B

Babak Pedram

Director

View 8 more team members with Pro

Unlock Full Team Directory

Recent News